FWD Hong Kong promotes cancer genomics via MAX platform

It aims to educate the public on the benefits of early cancer detection.

FWD Hong Kong has partnered with Roche Diagnostics (Hong Kong) and HKSH Cancer Centre to raise public awareness of precision cancer medicine, particularly Comprehensive Genomic Profiling (CGP), through its FWD MAX lifestyle platform.

The initiative aims to educate the public on the benefits of early cancer detection and personalised treatment strategies based on genomic data.

This collaboration follows data from the Hong Kong Cancer Registry showing that the overall five-year survival rate for cancer patients has risen from 42% in the early 2000s to 55% in recent years.

Through FWD MAX, users will gain access to content related to CGP and precision medicine, including educational material from oncologists at HKSH Cancer Centre. 

The initiative is part of FWD’s broader effort to expand its healthcare partner network and enhance public understanding of cancer care options beyond insurance.

HKSH Cancer Centre remains the only private medical institution in Hong Kong to offer in-house CGP testing, which can detect mutations in over 300 cancer-related genes in a single test without sending samples overseas. 

This shortens turnaround time and enables doctors to design timely and targeted treatment plans for patients.